research Granulomatous pigmented purpuric dermatosis containing Propionibacterium acnes
A medication may help with hair growth in psoriasis, and a skin condition might be linked to a specific bacteria.
Search
for
Sort by
Research
690-720 / 1000+ results 
research P79: Efficacy of baricitinib in adults with alopecia areata: patients’ perspectives on hair regrowth from two phase III randomized controlled trials (BRAVE‐AA1 and BRAVE‐AA2)
Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
research 586 Increase in CD8+ effector memory cells re-expressing CD45RA (TEMRA) reflects disease activity and enables early prediction of therapeutic outcome in rapidly progressive alopecia areata
Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
research Novel investigational drugs for alopecia areata and future perspectives
JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
research Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
research 050 Evaluation of 3 month data for the use of erenumab for chronic migraine in Glasgow
Erenumab significantly reduced migraine days or severity in most patients after 3 months.
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
research Increased risk of severe course of pemphigus in patients with pemphigus‐associated alopecia: a prospective observational study
Pemphigus patients with alopecia have more severe and treatment-resistant disease.
research Characterization of aberrant mTOR signaling pathway in U87MG glioblastoma cell line by quantitative phosphoproteomics
Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.
research Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
Biologics and JAK inhibitors may improve treatment for scarring alopecias.
research BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
research Scarring Alopecia in a 66‐Year‐Old Woman
A rare autoimmune disease caused the woman's scalp blisters and hair loss, successfully treated with medication.
research Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Folliculitis decalvans managed with adalimumab: A case report
Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
research Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
research Pharmacotherapy for diffuse alopecia
Selencin effectively reduces hair loss and improves hair health in diffuse alopecia.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
research Three-dimensional imaging for facial vitiligo: Results from a phase 2 randomized controlled trial investigating upadacitinib in patients with vitiligo
3D imaging effectively tracks skin changes in vitiligo treatment.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
research 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
research Nano-pulse stimulation™ therapy (NPS™) is superior to cryoablation in clearing murine melanoma tumors
Nano-Pulse Stimulation™ Therapy is more effective and less damaging than cryoablation for treating melanoma tumors in mice.
research Isolated hyperthermic chemotherapy perfusion for limb melanoma is a safe procedure
Isolated hyperthermic chemotherapy perfusion for limb melanoma is safe and effective with manageable side effects.
research Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
research The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
research MiR-325-3p functions as a suppressor miRNA and inhibits the proliferation and metastasis of glioma through targeting FOXM1
miR-325-3p can slow down brain tumor growth by targeting FOXM1.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.